Readmission with venous thromboembolism after surgical treatment by primary cancer site

Jarvis, Casey A.; Bonney, Phillip A.; Ding, Li; Tang, Austin M.; Giannotta, Steven L.; Kim, Anthony W.; Mack, William J.; Attenello, Frank J.

doi:10.1016/j.suronc.2020.09.013

Cited by 5 publications

(7 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are important differences in methodology between our study and theirs. The primary outcomes of our study were postoperative VTE as a primary cause of readmission, whereas Jarvis et al 40 reported VTE when listed as either a primary or secondary diagnosis. The latter approximates the overall rate of postoperative VTE, although it does not capture individuals treated entirely as outpatients, which is a significant proportion of patients.…”

Section: Discussionmentioning

confidence: 86%

“…The latter approximates the overall rate of postoperative VTE, although it does not capture individuals treated entirely as outpatients, which is a significant proportion of patients. Hence, the rates described by Jarvis et al have ascertainment bias. In contrast, our analysis accurately captures instances of VTE that were severe enough to warrant readmission.…”

Section: Discussionmentioning

confidence: 99%

“…An analysis of 90-and 180-day readmission with VTE after cancer surgery was recently conducted by Jarvis et al 40 The authors found a rate of admission with VTE of 1.7% at 90 days and 2.3% within 180 days. There are important differences in methodology between our study and theirs.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Readmissions From Venous Thromboembolism After Complex Cancer Surgery

et al. 2022

View full text Add to dashboard Cite

IMPORTANCE Venous thromboembolism (VTE) is a major cause of preventable morbidity and mortality after cancer surgery. Venous thromboembolism events that are significant enough to require hospital readmission are potentially life threatening, yet data regarding the frequency of these events beyond the 30-day postoperative period remain limited.OBJECTIVE To determine the rates, outcomes, and predictive factors of readmissions owing to VTE up to 180 days after complex cancer operations, using a national data set. DESIGN, SETTING, AND PARTICIPANTSA retrospective cohort study of the 2016 Nationwide Readmissions Database was performed to study adult patients readmitted with a primary VTE diagnosis. Data obtained from 197 510 visits for 126 104 patients were analyzed. This was a multicenter, population-based, nationally representative study of patients who underwent a complex cancer operation (defined as cystectomy, colectomy, esophagectomy, gastrectomy, liver/biliary resection, lung/bronchus resection, pancreatectomy, proctectomy, prostatectomy, or hysterectomy) from January 1 through September 30, 2016, for a corresponding cancer diagnosis. EXPOSURES Readmission with a primary diagnosis of VTE.MAIN OUTCOMES AND MEASURES Proportion of 30-, 90-, and 180-day VTE readmissions after complex cancer surgery, factors associated with readmissions, and outcomes observed during readmission visit, including mortality, length of stay, hospital cost, and readmission to index vs nonindex hospital. RESULTSFor the 126 104 patients included in the study, 30-, 90-, and 180-day VTE-associated readmission rates were 0.6% (767 patients), 1.1% (1331 patients), and 1.7% (1449 of 83 337 patients), respectively. A majority of patients were men (58.7%), and the mean age was 65 years (SD, 11.5 years). For the 1331 patients readmitted for VTE within 90 days, 456 initial readmissions (34.3%) were to a different hospital than the index surgery hospital, median length of stay was 5 days (IQR, 3-7 days), median cost was $8102 (IQR, $5311-$10 982), and 122 patients died (9.2%). Independent factors associated with readmission included type of operation, scores for severity and risk of mortality, age of 75 to 84 years (odds ratio [OR], 1.30; 95% CI, 1.02-1.78), female sex (OR, 1.23; 95% CI,, nonelective index admission (OR, 1.31; 95% CI, 1.03-1.68), higher number of comorbidities (OR, 1.30; 95% CI, 1.06-1.60), and experiencing a major postoperative complication during the index admission (OR, 2.08; 95% CI, 1.85-2.33). CONCLUSIONS AND RELEVANCEIn this cohort study, VTE-related readmissions after complex cancer surgery continued to increase well beyond 30 days after surgery. Quality improvement efforts to decrease the burden of VTE in postoperative patients should measure and account for these late VTE-related readmissions.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Readmissions From Venous Thromboembolism After Complex Cancer Surgery

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Although much of the literature on VTE during hospitalization for cancer surgery is dated, recent work by Mallick et al and Jarvis et al has demonstrated that the risk of VTE extends beyond the immediate postoperative period [ 6 , 7 ]. Accordingly, recommendations from several organizations including the American Society of Clinical Oncology and the American Society of Hematology have specifically targeted VTE prophylaxis among cancer patients in both the inpatient setting and postdischarge [ 8 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Venous thromboembolism in cancer surgery: A report from the nationwide readmissions database

Pan¹,

Sanaiha²,

Hadaya³

et al. 2022

Surgery Open Science

View full text Add to dashboard Cite

“…Breast cancer is caused by numerous factors including the environment (Cheng et al., 2022 ), heredity (Lee et al., 2022 ), and other factors (Ro et al., 2022 ). According to a summary of relevant papers published by Chinese clinicians on the treatment of breast cancer (Killelea et al., 2020 ; He et al., 2021 ), the current clinical treatment methods (Dinparvar et al., 2020 ; Liu et al., 2020 ) are mainly a combination of surgical treatment (Efetov et al., 2020 ; Jarvis et al., 2020 ; Webster et al., 2020 ) and chemotherapy (Guay et al., 2022 ; Karampinis et al., 2022 ), or radiotherapy (Yuan et al., 2020 ; Hashida et al., 2021 ; Hata et al., 2021 ; Wei et al., 2021) and targeted therapy (Chen et al., 2020 ). Currently, the chemotherapeutic drugs anthracycline and taxane are widely used in breast cancer and are the benchmark for future targeted therapies (Wala et al., 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Effect and mechanism of paclitaxel loaded on magnetic Fe ₃ O ₄ @mSiO ₂ -NH ₂ -FA nanocomposites to MCF-7 cells

Deng

Yin

et al. 2022

Drug Delivery

View full text Add to dashboard Cite

Magnetic Fe 3 O 4 nanoparticles were prepared via a simple hydrothermal method and utilized to load paclitaxel. The average particle size of Fe 3 O 4 nanoparticles was found to be 20.2 ± 3.0 nm, and the calculated saturation magnetization reached 129.38 emu/g, verifying superparamagnetism of nanomaterials. The specific surface area and pore volume were 84.756 m 2 /g and 0.265 cm 3 /g, respectively. Subsequently, Fe 3 O 4 @mSiO 2 nanoparticles were successfully fabricated using the Fe 3 O 4 nanoparticles as precursors with an average size of 27.81 nm. The relevant saturation magnetization, zeta potential, and specific surface area of Fe 3 O 4 @mSiO 2 -NH 2 -FA were respectively 76.3 emu/g, −14.1 mV, and 324.410 m 2 /g. The pore volume and average adsorption pore size were 0.369 cm 3 /g and 4.548 nm, respectively. Compared to free paclitaxel, the solubility and stability of nanoparticles loaded with paclitaxel were improved. The drug loading efficiency and drug load of the nanoformulation were 44.26 and 11.38%, respectively. The Fe 3 O 4 @mSiO 2 -NH 2 -FA nanocomposites were easy to construct with excellent active targeting performance, pH sensitivity, and sustained-release effect. The nanoformulation also showed good biocompatibility, where the cell viability remained at 73.8% when the concentration reached 1200 μg/mL. The nanoformulation induced cell death through apoptosis, as confirmed by AO/EB staining and flow cytometry. Western blotting results suggested that the nanoformulation could induce iron death by inhibiting Glutathione Peroxidase 4 (GPX4) activity or decreasing Ferritin Heavy Chain 1 (FTH1) expression. Subsequently, the expression of HIF-1α was upregulated owing to the accumulation of reactive oxygen species (ROS), thus affecting the expression of apoptosis-related proteins regulated by p53, inducing cell apoptosis.

show abstract

Readmission with venous thromboembolism after surgical treatment by primary cancer site

Cited by 5 publications

References 41 publications

Readmissions From Venous Thromboembolism After Complex Cancer Surgery

Readmissions From Venous Thromboembolism After Complex Cancer Surgery

Venous thromboembolism in cancer surgery: A report from the nationwide readmissions database

Effect and mechanism of paclitaxel loaded on magnetic Fe ₃ O ₄ @mSiO ₂ -NH ₂ -FA nanocomposites to MCF-7 cells

Contact Info

Product

Resources

About

Readmission with venous thromboembolism after surgical treatment by primary cancer site

Cited by 5 publications

References 41 publications

Readmissions From Venous Thromboembolism After Complex Cancer Surgery

Readmissions From Venous Thromboembolism After Complex Cancer Surgery

Venous thromboembolism in cancer surgery: A report from the nationwide readmissions database

Effect and mechanism of paclitaxel loaded on magnetic Fe 3 O 4 @mSiO 2 -NH 2 -FA nanocomposites to MCF-7 cells

Contact Info

Product

Resources

About

Effect and mechanism of paclitaxel loaded on magnetic Fe ₃ O ₄ @mSiO ₂ -NH ₂ -FA nanocomposites to MCF-7 cells